Ledipasvir API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
Country of origin
Follow us
Producer
ISO9001 certified
Drug R&D center (in Hangzhou)
From lab scale (mg/g) to commercial scale (kgs/tons)
+ 0
All certificates
Replies quickly
Producer
+ 0
All certificates
Replies slower than most
Producer
+ 0
All certificates
Replies slower than most
Replies slower than most
Distributor
+ 0
All certificates
Not active
Not active
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Ledipasvir API 1256388-51-8?
- Description:
- Here you will find a list of producers, manufacturers and traders of Ledipasvir. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ledipasvir
- Synonyms:
- Cas Number:
- 1256388-51-8
- DrugBank number:
- DB09027
- Unique Ingredient Identifier:
- 013TE6E4WV
About Ledipasvir
It's time for some technical information for the ones who understand chemistry: Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients Treatment options for chronic Hepatitis C have advanced significantly since 20 with the development of Direct Acting Antivirals (DAAs) such as ledipasvir. More specifically, ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural Protein 5A (NS5A), which is required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required for viral protein production.
It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV. Ledipasvir and other direct acting antivirals are very potent options for the treatment of Hepatitis C, as they exhibit a high barrier to the development of resistance This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements.
Ledipasvir is a type of HCV polymerase inhibitors
HCV polymerase inhibitors are a vital subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the treatment of Hepatitis C virus (HCV) infections. These inhibitors target the RNA-dependent RNA polymerase (NS5B) enzyme, which plays a crucial role in the replication of the HCV virus within human cells.
By specifically inhibiting NS5B, these pharmaceutical compounds effectively hinder viral replication, reducing viral load and helping to control the progression of HCV infection. HCV polymerase inhibitors are commonly used in combination with other antiviral agents, such as direct-acting antivirals (DAAs), to achieve optimal therapeutic outcomes.
One of the key advantages of HCV polymerase inhibitors is their high potency and specificity against the NS5B enzyme, which minimizes the risk of off-target effects and increases the likelihood of successful treatment. Moreover, these inhibitors have shown excellent efficacy against a broad range of HCV genotypes, making them suitable for patients with diverse viral strains.
Researchers and pharmaceutical companies continue to innovate and develop new HCV polymerase inhibitors with enhanced efficacy and improved safety profiles. Ongoing efforts in this field aim to expand treatment options, reduce treatment durations, and improve the overall cure rates for patients infected with HCV.
In conclusion, HCV polymerase inhibitors are essential components of modern antiviral therapy for Hepatitis C. Their targeted inhibition of the NS5B enzyme demonstrates significant clinical benefits, providing patients with more effective and personalized treatment options, ultimately improving their quality of life.
Ledipasvir (HCV polymerase inhibitors), classified under Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Ledipasvir manufacturers | traders | suppliers
We have 6 companies offering Ledipasvir produced in 3 different countries.
Get in contact with the supplier of your choice:
- Senova Technology Co., Ltd. from China, product country of origin China
- Dalian Wista Pharma Co Ltd from China, product country of origin China
- Natco Pharma from India, product country of origin India
- PCAS from France, product country of origin France
- Shaoxing Hantai Pharma from China, product country of origin China
- Mylan from India, product country of origin India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
